In de novo PD patients, baseline CSF GFAP levels also predicted the longitudinal increase of CSF Aβ42 (β = 0.147, p = 0.034), T-tau (β = 0.337, p < 0.001), and P-tau (β = 0.408, p < 0.001), α-syn (β = 0.313, p < 0.001) (Fig. 2a and Additional file 1: Table S3 Model 1). Here, GFAP is linked to Parkinson disease.